RE: Old but informational - 10 - 20 mill mcap on deal16 Oct 2022 12:11
I know it's hard being a troll researching the most recent RNS's to learn about a share then to bash it.
However Anne Brindley/NFX already had this idea in the pipeline early 2021. Preliminary studies had already been done in 2021 showing promising results.. If the results weren't promising then they probably wouldn't consider this quickly accepted and cheaper method of research.
https://www.lse.co.uk/rns/NFX/research-results-nn5ek5npkhs2elh.html
Dr Lee Borthwick, Senior Lecturer in Fibrosis Biology at the Newcastle Fibrosis Research Group, Newcastle University, said: "The data from this most recent study of Nuformix's drug candidate, NXP002, are very encouraging in combination with current IPF drugs and show clear attenuation of both fibrosis and inflammatory markers in combination with pirfenidone or nintedanib. This reinforces previous work done in our laboratories on this compound."
Dr Anne Brindley, CEO of Nuformix, said: "IPF is a devastating disease with few treatment options and there is a real need for new therapies that are efficacious but that have better tolerability than the current therapies on the market. IPF is likely to become a combination market in the future. The results of this ex-vivo study in IPF are very encouraging and suggest the potential benefit of using NXP002 in combination with standard of care treatments for IPF. These results underpin NXP002's potential and demonstrate that further development of NXP002 for the treatment of IPF is warranted."